Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Kansas City, Missouri

Cancer surgery and procedure trials in Kansas City, MO

42 cancer surgery and procedure studies are recruiting participants at sites in Kansas City as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Kansas City at a glance

  • 42 studies are recruiting at a site in Kansas City.
  • By phase: Phase 1/2 (2), Phase 2 (10), Phase 2/3 (1), Phase 3 (26), No phase (2), Observational (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (26), government (16).
  • By research area: Lymphoma (14), Lung Cancer (11), Breast Cancer (8), Prostate Cancer (5), Melanoma (2), Pancreatic Cancer (2).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Kansas City

Basic details from each study's public record (the 30 most recently updated of 42). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kansas City Veterans Affairs Medical Center · Saint Luke's Hospital of Kansas City
    Registry record
    NCT06995898 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT07391774 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT06058377 · updated
  4. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Kansas City Veterans Affairs Medical Center
    Registry record
    NCT05334069 · updated
  5. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Kansas City, MO on ClinicalTrials.gov.

Lung cancer studies recruiting in Kansas City

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University Health Truman Medical Center
    Registry record
    NCT06498635 · updated
  2. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT07388524 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Saint Luke's Hospital of Kansas City
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Kansas City Veterans Affairs Medical Center
    Registry record
    NCT06096844 · updated
  5. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT06031688 · updated
  6. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT06116682 · updated
  7. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Kansas City Veterans Affairs Medical Center · University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Kansas City, MO on ClinicalTrials.gov.

Prostate cancer studies recruiting in Kansas City

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University Health Truman Medical Center
    Registry record
    NCT03866382 · updated
  2. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT06931340 · updated
  3. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study site
    University of Kansas Cancer Center - North
    Registry record
    NCT05946213 · updated
  4. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    SWOG Cancer Research Network
    Study site
    University of Kansas Cancer Center - North
    Registry record
    NCT03678025 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Kansas City, MO on ClinicalTrials.gov.

Melanoma studies recruiting in Kansas City

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Kansas City, MO on ClinicalTrials.gov.

Lymphoma studies recruiting in Kansas City

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Mercy Hospitals and Clinics
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kansas City Veterans Affairs Medical Center · University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff
    Registry record
    NCT06337318 · updated
  3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's Mercy Hospitals and Clinics
    Registry record
    NCT04726241 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study sites
    University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT06724237 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kansas City Veterans Affairs Medical Center · University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Mercy Hospitals and Clinics
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Mercy Hospitals and Clinics
    Registry record
    NCT05675410 · updated
  8. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Kansas City Veterans Affairs Medical Center · University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff
    Registry record
    NCT05976763 · updated
  9. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT07215910 · updated
  10. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University Health Truman Medical Center · University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT07321652 · updated
  11. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Mercy Hospitals and Clinics
    Registry record
    NCT06124157 · updated
  12. Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Kansas Cancer Center - Briarcliff · University of Kansas Cancer Center - North
    Registry record
    NCT05886036 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Kansas City, MO on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Kansas City

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Saint Luke's Hospital of Kansas City · University Health Truman Medical Center · University of Kansas Cancer Center - North
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Kansas City, MO on ClinicalTrials.gov.

Ask about studies near Kansas City

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Missouri

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call